129 related articles for article (PubMed ID: 37943779)
1. Correction: Effect of body tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors.
Makrakis D; Rounis K; Tsigkas AP; Georgiou A; Galanakis N; Tsakonas G; Ekman S; Papadaki C; Monastirioti A; Kontogianni M; Gioulbasanis I; Mavroudis I; Agelaki S
PLoS One; 2023; 18(11):e0294384. PubMed ID: 37943779
[TBL] [Abstract][Full Text] [Related]
2. Correction: Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study.
Rounis K; Makrakis D; Papadaki C; Monastirioti A; Vamvakas L; Kalbakis K; Gourlia K; Xanthopoulos I; Tsamardinos I; Mavroudis D; Agelaki S
PLoS One; 2023; 18(11):e0294382. PubMed ID: 37943834
[TBL] [Abstract][Full Text] [Related]
3. Erratum to cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: results from a prospective, observational study.
Editorial Office
Transl Lung Cancer Res; 2023 Oct; 12(10):2146-2147. PubMed ID: 38025815
[TBL] [Abstract][Full Text] [Related]
4. Correction: Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms.
Ilie M; Khambata-Ford S; Copie-Bergman C; Huang L; Juco J; Hofman V; Hofman P
PLoS One; 2017; 12(10):e0186537. PubMed ID: 29028832
[TBL] [Abstract][Full Text] [Related]
5. Correction: PCC0208025 (BMS202), a small molecule inhibitor of PD-L1, produces an antitumor effect in B16-F10 melanoma-bearing mice.
PLOS ONE Staff
PLoS One; 2021; 16(4):e0251020. PubMed ID: 33909703
[TBL] [Abstract][Full Text] [Related]
6. Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.
Ferrara R; Mezquita L; Texier M; Lahmar J; Audigier-Valette C; Tessonnier L; Mazieres J; Zalcman G; Brosseau S; Le Moulec S; Leroy L; Duchemann B; Lefebvre C; Veillon R; Westeel V; Koscielny S; Champiat S; Ferté C; Planchard D; Remon J; Boucher ME; Gazzah A; Adam J; Bria E; Tortora G; Soria JC; Besse B; Caramella C
JAMA Oncol; 2018 Nov; 4(11):1543-1552. PubMed ID: 30193240
[TBL] [Abstract][Full Text] [Related]
7. Indirect comparison of sintilimab and other PD-L1 inhibitors for first-line treatment of non-squamous non-small-cell lung cancer.
Zhang L; Qian Y; Li J; Cui C; Chen L; Qu S; Lu S
Future Oncol; 2022 May; 18(15):1896-1905. PubMed ID: 35311347
[TBL] [Abstract][Full Text] [Related]
8. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
[No Abstract] [Full Text] [Related]
9. Real-world study of PD-L1 testing patterns and treatment distribution in patients with metastatic non-small-cell lung cancer in Israel.
Moser SS; Apter L; Arunachalam A; Burke T; Shalev V; Chodick G; Siegelmann-Danieli N
Immunotherapy; 2021 Jul; 13(10):851-861. PubMed ID: 34034511
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 expression as a prognostic marker in patients treated with chemotherapy for metastatic non-small-cell lung cancer.
Woodford R; Zhou D; Lord SJ; Marschner I; Cooper WA; Lewis CR; John T; Yang JC; Lee CK
Future Oncol; 2022 May; 18(14):1793-1799. PubMed ID: 35156837
[TBL] [Abstract][Full Text] [Related]
11. Serum immune mediators as novel predictors of response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients with high tissue-PD-L1 expression.
Raza A; Mohsen R; Kanbour A; Zar Gul AR; Philip A; Vijayakumar S; Hydrose S; Prabhu KS; Al-Suwaidi AK; Inchakalody VP; Merhi M; Abo El-Ella DM; Tauro MA; Akbar S; Al-Bozom I; Abualainin W; Al-Abdulla R; Sirriya SA; Hassnad S; Uddin S; Mohamed Ibrahim MI; Al Homsi U; Demime S
Front Immunol; 2023; 14():1157100. PubMed ID: 37256148
[TBL] [Abstract][Full Text] [Related]
12. Quality of life in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: a systematic review and meta-analysis.
Liu W; Zhang Q; Zhang T; Li L; Xu C
World J Surg Oncol; 2022 Oct; 20(1):333. PubMed ID: 36192730
[TBL] [Abstract][Full Text] [Related]
13. Real-world utilization of PD-1/PD-L1 inhibitors with palliative radiotherapy in patients with metastatic non-small cell lung cancer.
Zhou ZC; Chen KY; Li N; Xie MY; Sheng JM; Fan Y; Huang ZY
Thorac Cancer; 2022 Aug; 13(16):2291-2300. PubMed ID: 35762488
[TBL] [Abstract][Full Text] [Related]
14. Real-world evidenceand clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors.
Song P; Zhang J; Shang C; Zhang L
Sci Rep; 2019 Mar; 9(1):4278. PubMed ID: 30862891
[TBL] [Abstract][Full Text] [Related]
15. Significance of PD-L1 expression in the cytological samples of non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Hara N; Ichihara E; Harada D; Inoue K; Fujiwara K; Hosokawa S; Kishino D; Haruyuki K; Ochi N; Oda N; Hotta K; Maeda Y; Kiura K
J Cancer Res Clin Oncol; 2021 Dec; 147(12):3749-3755. PubMed ID: 33779840
[TBL] [Abstract][Full Text] [Related]
16. Effect of PD-L1 Expression for the PD-1/L1 Inhibitors on Non-small Cell Lung Cancer: A Meta-analysis Based on Randomised Controlled Trials.
Xu Z; Liang J; Fu R; Yang L; Xin Chen Y; Ren W; Lu Y; Qiu X; Gu Q
Clin Oncol (R Coll Radiol); 2023 Oct; 35(10):640-651. PubMed ID: 37563075
[TBL] [Abstract][Full Text] [Related]
17. Brain metastases, patterns of intracranial progression, and the clinical value of upfront cranial radiotherapy in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors.
Guo T; Chu L; Chu X; Yang X; Li Y; Zhou Y; Xu D; Zhang J; Wang S; Hu J; Chu Q; Moran T; Cho WC; Merrell KW; Rizzo S; Liu Y; Ni J; Zhu Z
Transl Lung Cancer Res; 2022 Feb; 11(2):173-187. PubMed ID: 35280308
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Value of PD-L1 mRNA Sequencing Expression Profile in Non-Small Cell Lung Cancer.
Sepesi B; Nelson DB; Mitchell KG; Gibbons DL; Heymach JV; Vaporciyan AA; Swisher SG; Roszik J
Ann Thorac Surg; 2018 Jun; 105(6):1621-1626. PubMed ID: 29510096
[TBL] [Abstract][Full Text] [Related]
19. Correction: PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability.
Munari E; Zamboni G; Marconi M; Sommaggio M; Brunelli M; Martignoni G; Netto GJ; Moretta F; Mingari MC; Salgarello M; Terzi A; Picece V; Pomari C; Lunardi G; Cavazza A; Rossi G; Moretta L; Bogina G
Oncotarget; 2018 Dec; 9(97):37077. PubMed ID: 30651938
[TBL] [Abstract][Full Text] [Related]
20. Association between CD8+ tumor-infiltrating lymphocytes and prognosis of non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitors: a systematic review and meta-analysis.
Zheng QM; Li YY; Wang YP; Li GX; Zhao MM; Sun ZG
Expert Rev Anticancer Ther; 2023 Jun; 23(6):643-659. PubMed ID: 37114477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
